GlassScriptPhysician profile
Halyna Kuzyshyn
NPI 1770854499
$4,412.76
in general payments reported to CMS, 2019-2025
38 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $229 · 2021: $238 · 2022: $694 · 2023: $686 · 2024: $532 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $931.51 | 2019-2025 | |
| Amgen INC. | $494.56 | 2019-2025 | Krystexxa, Enbrel, Tavneos |
| Glaxosmithkline, LLC. | $400.68 | 2019-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $258.90 | 2022-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $252.29 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $189.37 | 2022-2025 | Lupkynis |
| Pfizer INC. | $178.33 | 2019-2025 | |
| Janssen Biotech, INC. | $157.35 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $156.61 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $136.32 | 2019-2025 | Orencia |
| Janssen Scientific Affairs, LLC | $124.99 | 2019 | |
| Ucb, INC. | $113.56 | 2019-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $108.50 | 2020-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $101.36 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Kiniksa Pharmaceuticals, LTD. | $86.33 | 2022-2023 | Arcalyst |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Halyna Kuzyshyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.